Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
SBHMY SINO BIOPHARMACEUT
9.7600.0000.00%
YOY
Do not show
Hide blank lines
(FY)2021/12/31(FY)2020/12/31(Q4)2020/12/31(Q3)2020/09/30
Total revenue
13.59% 26.86B -2.42% 23.65B 12.38% 5.52B -19.36% 5.48B
Operating revenue
13.59% 26.86B -2.42% 23.65B 12.38% 5.52B -19.36% 5.48B
Cost of revenue
2.89% 5.33B 5.20% 5.18B -4.10% 1.11B -2.77% 1.28B
Gross profit
16.60% 21.53B -4.37% 18.46B 17.44% 4.41B -23.36% 4.2B
Operating expense
21.36% 17.19B -0.39% 14.16B 28.50% 3.66B -17.90% 3.09B
Selling and administrative expenses
9.25% 12.7B -2.35% 11.63B 14.43% 2.97B -12.10% 2.94B
-Selling and marketing expense
17.23% 10.52B -3.72% 8.97B 22.44% 2.11B -15.45% 2.25B
-General and administrative expense
-17.72% 2.19B 2.58% 2.66B -1.35% 862.62M 1.07% 683.43M
Other operating expenses
69.62% 4.64B 6.98% 2.74B 85.68% 863.76M -63.37% 158.28M
Operating profit
0.91% 4.34B -15.46% 4.3B -17.09% 755.64M -35.33% 1.11B
Net non-operating interest income expense
-13.29% -146.56M -566.03% -129.37M -1,472.08% -71.16M -726.47% -36.66M
Non-operating interest income
-16.47% 162.06M -24.72% 194M -113.01% -13.25M 2.96% 54.48M
Non-operating interest expense
-4.56% 308.62M 40.63% 323.37M -40.09% 57.91M 93.64% 91.14M
Other net income (expense)
Special income (charges)
-18.54% 3.73M 407.20% 4.58M 127.34% 4.12M -99.32% 108K
-Less:Other special charges
18.54% -3.73M -407.20% -4.58M -127.34% -4.12M -- -108K
Other non- operating income (expenses)
385.63% 326.33M 37.33% 67.2M -13.85% -8.73M 7.19% 24.3M
Income before tax
270.49% 18.57B -10.22% 5.01B 15.83% 1.27B -35.94% 1.19B
Income tax
191.19% 1.96B -24.41% 672.38M -284.15% -105.32M -37.33% 239.8M
Net income
282.77% 16.61B -7.53% 4.34B 32.30% 1.38B -35.58% 946.24M
Net income continuous Operations
282.77% 16.61B -7.53% 4.34B 32.30% 1.38B -35.58% 946.24M
Minority interest income
27.83% 2.01B -21.03% 1.57B -22.51% 457.51M -53.05% 308.82M
Net income attributable to the parent company
427.17% 14.61B 2.38% 2.77B 104.00% 920.59M -21.42% 637.42M
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
427.17% 14.61B 2.38% 2.77B 104.00% 920.59M -21.42% 637.42M
Basic earnings per share
428.02% 15.566 2.46% 2.948 102.05% 0.986 -21.32% 0.6767
Diluted earnings per share
397.01% 14.652 2.46% 2.948 102.05% 0.986 -21.32% 0.6767
Dividend per share
-15.21% 0.9983 23.52% 1.1773 40.66% 0.337 45.40% 0.3523
Currency Unit
CNYCNYCNYCNY

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.
CEO: Mr. Yi Li
Market: Pink Market
Listing Date: 12/08/2003
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist